BCL2-associated agonist of cell death (BAD) (BAD)

BCL2-associated agonist of cell death (BAD) is a pro-apoptotic member of the BCL-2 protein family, specifically classified as a BH3-only protein [UniProt: Q92934]. It functions as a critical regulator of the intrinsic apoptotic pathway by binding to and neutralizing anti-apoptotic proteins such as BCL-2, BCL-XL, and BCL-W, thereby promoting the release of cytochrome c from the mitochondria [PubMed: 15706060]. The activity of BAD is tightly regulated by phosphorylation; when phosphorylated by kinases like Akt or PKA, it is sequestered in the cytosol by 14-3-3 proteins, preventing its pro-apoptotic action [PubMed: 9311998]. In many cancers, BAD is inactivated through over-phosphorylation or downregulation, allowing malignant cells to evade programmed cell death [PubMed: 20308501]. Consequently, BAD has served as the biological blueprint for the development of BH3 mimetics, a class of small-molecule drugs designed to replicate its inhibitory effect on anti-apoptotic proteins [PubMed: 26447168]. These drugs, such as venetoclax, have shown significant clinical success in treating hematologic malignancies by restoring the apoptotic threshold. Beyond its role in cell death, BAD is also involved in regulating glucose metabolism through its interaction with glucokinase in the mitochondria [PubMed: 12842088].

Other names

BCL2-associated death promoterBCL2-binding component 6BCL2L8BBC2BCL2-binding protein

BH3 mimetic; competitive inhibition of anti-apoptotic BCL-2 family members (BCL-2, BCL-XL, BCL-W) to trigger apoptosis by displacing pro-apoptotic factors or mimicking BAD activity.